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OBJECTIVES The present study was conducted to determine the safety of the transcatheter closure of a
patent foramen ovale (PFO) in patients with cryptogenic cerebral ischemia and the midterm
follow-up of recurrent thromboembolic events after interventional PFO closure.
BACKGROUND Current therapeutic options for stroke prevention in patients with PFO and a history of
thromboembolic events include chronic antithrombotics and more invasive treatments such as
surgical closure or minor invasive transcatheter permanent closure of the PFO. Promising
preliminary and pilot data with the Amplatzer Septal Occluder or the PFO-Star Occluder
have been reported. Systematic and long-term data are still missing.
METHODS A total of 276 consecutive patients with a PFO and a history of at least one thromboembolic
event were recruited in four medical centers and underwent percutaneous PFO closure with
the PFO-Star device. Follow-up data were analyzed over an average of 15.1 months,
equivalent to 345 patient-years.
RESULTS The implantation was successful in all 276 patients. Peri-interventional reversible complica-
tions included transient ST-segment elevations (1.8%) and transient ischemic attack (TIA)
(0.8%). Two devices have been removed surgically. During follow-up the annual recurrence
rate of thromboembolic events was 1.7% for TIA, 0% for stroke and 0% for peripheral emboli.
CONCLUSIONS Interventional PFO closure with the PFO-Star device appears to be a reliable and promising
technique resulting in a low recurrence rate of thromboembolic events, especially stroke in
patients with a history of cryptogenic ischemia presumably due to paradoxical embolization.
To our knowledge, this is the largest coherent and prospective study for interventional PFO
closure. (J Am Coll Cardiol 2002;39:2019–25) © 2002 by the American College of
Cardiology Foundation
Patients with cryptogenic transient ischemic attack (TIA) or
ischemic stroke revealed a high prevalence of a patent
foramen ovale (PFO) in up to 40% to 50% of cases (1),
suggesting the PFO as a potential risk factor for ischemic
stroke due to paradoxical embolism. The incidence of
recurrent thromboembolic events in these patients is vari-
able and ranges between 0% and 14% (2,3). Three large and
recent studies demonstrated the long-term prognosis of
nonselected patients with PFO and stroke, reporting a
stroke recurrence rate of 1% to 2%/year, whereas the
cumulative annual risk for stroke or TIA was 2% to 4%
(4–6). An atrial septal aneurysm (ASA) has been identified
as another source for cardiogenic embolism and is frequently
associated with a PFO (4,7).
Therapeutic options for secondary stroke prevention in
patients with a PFO include two major strategies: 1) the
conservative strategy of long-term medical treatment with
antithrombotic therapy (platelet antiaggregating drugs) or
oral anticoagulation, and 2) the invasive strategy with
surgical or interventional closure of the atrial septal defect
(8). A variety of studies have shown that the recurrence rate
of thromboembolic events in patients with a PFO receiving
oral anticoagulation is lower than in patients treated with
aspirin (3). However, major bleeding complications of oral
anticoagulation correlate with the intensity and duration of
anticoagulant therapy (9). Surgical closure of the PFO in
patients with paradoxical embolization has been reported by
Homma et al. (10) and Ochsenfahrt et al. (11). However,
sufficient follow-up data on large patient populations for
surgical intervention in preventing stroke recurrence are still
lacking.
The percutaneous PFO closure using self-expanding
double disc devices such as the Amplatzer Septal Occluder
or the PFO-Star Occluder may provide an alternative
technique to prevent paradoxical embolism (12,13). The
present study analyzes 276 consecutive patients with a PFO
and a history of cryptogenic cerebral ischemia for up to 34
months after transcatheter PFO closure.
PATIENTS AND METHODS
Patient population. From April 1998 until February 2001,
276 consecutive patients with a PFO and at least one
documented TIA or stroke underwent transcatheter closure
of the defect according to the study protocol approved by
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the local ethics committee. All patients gave written in-
formed consent.
Patients with the following criteria were included: 1)
presence of a PFO with spontaneous or provokable right-
to-left shunting as confirmed by contrast transesophageal
echocardiography (TEE), or 2) history of a cryptogenic
cerebral ischemia (TIA or stroke) confirmed clinically by a
neurologist. A TIA was characterized as a transient and
reversible neurologic deficit lasting 12 h, whereas a stroke
lasted24 h and might result in a residual neurologic motor
or sensory disability. All patients received cerebral imaging
either by cerebral computer tomography (CT) or magnetic
resonance imaging (MRI). Patients with any other identi-
fiable cardiovascular thromboembolic risk were excluded,
such as the following: 1) arteriosclerotic plaques in the
ascending aorta or extracranial arteries as determined by
sonography; 2) cardiac arrhythmias such as atrial fibrillation
as determined by history, 12-lead electrocardiogram (ECG)
or 24-h Holter ECG; 3) prothrombotic coagulation distur-
bances as determined by extensive coagulation blood tests
including protein C and S, antithrombin III, fibrinogen,
antiphospholipid antibodies and APC resistance; and 4) all
patients with other indications for oral anticoagulation, such
as severe decreased left ventricular systolic function or an
implanted prosthetic valve.
Degree of right-to-left shunt. The degree of interatrial
shunting across the PFO was determined by multiplane
TEE (HP Sonos 5500, Hewlett Packard, Palo Alto, Cali-
fornia). The maximum number of microbubbles seen in the
left atrium in any single frame after intravenous contrast
injection during Valsalva maneuver was used to quantify the
shunt size. A “small” degree of shunt was defined as 3 to 20
bubbles and a “large” degree as 20 bubbles. According to
Mu¨gge et al. (7), an ASA was defined as an interatrial
septum of abnormal mobility with protrusion of the septum
into the left or right atrium of at least 10 mm beyond the
baseline.
PFO-Star device and the implantation procedure. The
PFO-Star is a self-locating and self-expanding device con-
sisting of two Ivalon-square discs (Fig. 1, left). Each
umbrella has a diameter of 18 mm, 22 mm, 26 mm, 30 mm
or 35 mm and is expanded by four or six nitinol arms. Three
different generations of PFO-Star devices (generation I to
III) were used in this study, representing technical progress
in the development of the device system. Generation I
devices were constructed with 2-mm center posts, 2-mm-
thick foam Ivalon sails and titanium protective end caps.
Generation II introduced new 3-mm and 5-mm center
posts to accommodate variations in septal thickness. Thick-
ness of the Ivalon sail was reduced to improve endotheliza-
tion of the implanted device and to allow the use of smaller
delivery sheath sizes (10F). Generation III devices were
constructed with the left-side Ivalon attached on the outside
of the frame.
Interventional procedures were performed under local
(96.4% of patients) or general (3.6% of patients) anesthesia.
Venous access was gained via the right femoral vein and the
PFO was passed with a standard exchange wire using a
6F-multipurpose catheter under fluoroscopic and TEE
guidance. All patients were anticoagulated with 10,000 U
heparin and received 1.2 g amoxycillin intravenously (IV)
and 0.5 to 1.0 mg atropin IV to prevent endocarditis and
catheter-induced coronary spasm. The stretched diameter of
the PFO was defined by balloon sizing. After the 6F-
multipurpose catheter was changed to a 10 to 12 F trans-
septal sheath, the selected PFO-Star device was attached to
Abbreviations and Acronyms
ASA  atrial septal aneurysm
CT  computer tomography
ECG  electrocardiogram
IV  intravenous/intravenously
MRI  magnetic resonance imaging
PFO  patent foramen ovale
TEE  transesophageal echocardiography
TIA  transient ischemic attack
Figure 1. Original patent foramen ovale-Star occluder is demonstrated with the center post, the expanded nitinol wires and the two Ivalon sails (left). After
implantation the device is shown by transesophageal echocardiography in the vertical biatrial view (middle) and by magnetic resonance imaging in the
four-chamber view (right). Ao  aorta; LA  left atrium; RA  right atrium.
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the delivery forceps and loaded into the trans-septal sheath
while the system was flushed with saline. The device was
advanced in the left atrium. Under fluoroscopic and TEE
control the sheath and the partially expanded device were
pulled back until contact to the interatrial septum was
achieved. In this position the sheath was further pulled back
to expand the right atrial disc of the PFO-Star occluder.
After correct position of the device was confirmed, it was
released from the forceps (Fig. 1, middle). All procedures
were performed under multiplane TEE guidance. In some
of the later patients magnetic resonance imaging (turbo-
spin-echo and gradient-echo-sequence, Magnetom, Sie-
mens, Munich, Germany) was performed during follow-up
(after six months) on a 1.5 T whole-body scanner (Fig. 1,
right).
Postinterventional treatment. Postinterventional treat-
ment included oral aspirin (100 mg once a day) for 12
months, clopidogrel (75 mg once a day) for 6 weeks and
low-dose heparin for the first 3 days after intervention. To
prevent infectious complications, amoxycillin (0.625 g bid)
was given for 3 days. Prophylaxis of infectious endocarditis
was performed for six months according to the guidelines of
the American Heart Association.
Postprocedural control and follow-up. A transthoracic
echocardiography was performed within the first few days
after transcatheter PFO closure. All patients were followed
up prospectively for up to 34 months. After percutaneous
PFO closure, clinical examinations were carried out at
1 month, 6 months, 12 months and every 12 months
thereafter, including neurologic and medical examination, a
12-lead-ECG and a contrast TEE (Echovist, Schering AG,
Berlin, Germany) at rest and during Valsalva maneuver.
The neurologic examinations were performed by neurolo-
gists. Patients with suspected recurrent thromboembolic
events were reevaluated by their neurologist and additionally
by cerebral CT and/or MRI.
Statistical analysis. Analyses of the data included the
description of peri-interventional event rates and complica-
tions as well as the complications during the follow-up
period. No further statistical analyses were included.
RESULTS
Patients. A total of 276 patients with a PFO and a
cryptogenic cerebral or peripheral thromboembolic event
underwent transcatheter closure with a PFO-Star device.
The patients’ characteristics are shown in Table 1. An ASA
was present in 62 patients (22%) and a hypermobile septum
(as a minor form of an ASA) was present in 31 patients
(11%). Cardiovascular arteriosclerotic promoters such as
smoking (36%), systemic hypertension (15%), hyperlipid-
emia (11%) and diabetes mellitus (7%) have been identified.
Implantation procedure of the PFO-Star system. The
implantation procedure was performed successfully in all
276 patients (100%). General anesthesia was required in 10
patients (3.6%). Three different generations of the PFO-
Star device were used: generation I in 14% (n  38),
generation II in 27% (n  74) and generation III in 59%
(n  164) of the patients. The sizes of the devices were
18 mm (n  2), 22 mm (n  25), 26 mm (n  94), 30 mm
(n  139) and 35 mm (n  16). Trans-septal puncture was
necessary in one patient because of the short distance of the
PFO channel to the anterior mitral valve leaflet. Procedural
time ranged from 9 to 48 min (mean: 24  8 min), with
fluoroscopy times of 1.4 to 10.2 min (mean: 4.1 2.3 min).
Peri-interventional complications (within 24 h). Device
implantation was performed successfully in all patients. The
overall peri-interventional complication rate was 4% (11 of
276 patients); most complications were minor and all were
reversible (Table 2, upper part). Four patients developed
transient ST-segment elevations in the inferior leads, pre-
sumably due to air embolism through the trans-septal
sheath during device delivery or to mechanically induced
spasm of the coronary arteries. The ECG changes resolved
within 3 min. In one patient an additional reversible
atrioventricular block III developed, with a slow ventricular
escape rhythm requiring temporary pacing. In two patients
a reversible peri-interventional TIA was observed. One of
these patients suffered a right arm paresis, the other a mild
left hemiparesis. These neurologic symptoms completely
resolved within 4 h. No irreversible cerebral or peripheral
ischemic events related to the implantation procedure oc-
curred. Most complications were observed in the early phase
of the study, likely because of the original cumbersome
underwater introduction system, which may have produced
embolization of small air bubbles. After the introduction
system was changed to a more practicable and safer high-
pressure flushing-loading system, and additionally through
the learning curve of the physicians, peri-interventional
complications were significantly reduced. Major complica-
tions occurred in 2 of 276 patients (0.8%). In one patient, a
30-mm generation II device embolized in the systemic
circulation and was successfully removed with a snare from
the bifurcation of the aorta. Dislodgement of the device into
the proximal orifice of the PFO channel after the device was
released from guidewire forceps has been observed in
another patient, who had a relatively long PFO channel.
According to repetitive TEEs the position of the device was
Table 1. Patient Characteristics
Number of patients 276






Average incidence of embolic events
before PFO closure
3.9 %/year
Hypermobile septum 31 (11%)
Atrial septum aneurysm 62 (22%)
Mean follow-up period (range) 15.1  5.8 months
(3–34 months) 345 patient-years
PFO  patent foramen ovale; TIA  transient ischemic attack.
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stable without further significant dislocation. Because of low
warfarin compliance, the patient preferred surgical removal
of the device 12 days after intervention and recovered
without any problems.
Follow-up. The total follow-up time of 276 consecutive
patients was 345 patient-years; the mean follow-up interval
was 15.1 months (Table 2, bottom part).
Clinical examination. Clinical examination of the patients
revealed mild unspecific thoracic sensations in a small
percentage (9.4%) of all patients within the first four weeks
after device implantation. The reason for these symptoms is
unknown. However, it has been observed that antiphlogistic
drugs such as ibuprofen diminish these symptoms, support-
ing the notion that postinterventional inflammation might
be involved. One patient developed an allergic-like skin
reaction of unknown etiology one week after implantation.
Although it was not certain that the device was causative,
the system was surgically removed and the PFO was closed
at the same time. However, the histologic examination of
the device-associated atrial tissue revealed no inflammation
or infiltration, suggesting that not the device itself but
another antigen was responsible for the allergic skin reac-
tion.
Recurrent thromboembolic events. During follow-up, six
recurrent TIAs (1.7%/year) were encountered after the
PFO-Star device was implanted (Table 2, bottom part;
Table 3). Strokes or peripheral arterial embolism have not
been observed. All thromboembolic events occurred within
the first six months after transcatheter closure of the PFO
and were completely resolved within 30 min after onset.
No thromboembolic event was observed 6 months after
PFO closure. One patient, who had a minimal residual
shunt, suffered a transient aphasia during a hypertensive
crisis. Cranial CT scan did not show any new defect and the
symptoms resolved completely. In the other five patients, no
residual shunt of the closed PFO was found by contrast-
TEE at rest and during Valsalva maneuver, suggesting other
reasons than the PFO were responsible for these TIAs. In
all these cases repeated TEEs and/or fluoroscopic evaluation
demonstrated the PFO-Star device in the correct position,
with no evidence of dislocation, arm fracture or thrombus
formation on the device.
One of these patients still had a positive bubble test,
suggesting a right-to-left shunt at a different site than the
PFO or the atrial septum. Another patient had a newly
discovered arterosclerotic lesion of the right internal carotid
artery as possible cause for the TIA. A third patient
underwent cerebral angiography after the recurrent ischemic
event. An intracerebral arteriovenous fistula was detected
and the patient underwent neurosurgical ligation with
uneventful outcome. Other potential risk factors for throm-
boembolic events such as an ASA or a hypermobile septum
were only present in one patient with a recurrent TIA.
During the follow-up period after interventional PFO
closure, the annual risk of recurrent TIA in patients with a
PFO alone was 2.1% and 0.9% in those with both PFO and
ASA. Cardiovascular risk factors could be identified in all
cases with a recurrent TIA (Table 3).
In conclusion, the average annual recurrence rate after
transcatheter closure of the PFO with a PFO-Star device





Overall complications 11 4.0
Minor complications 9 3.2
Reversible ST-segment elevations 4 1.8
Reversible AV block III 1 0.4
TIA 2 0.8
Stroke 0 0




Major complications 2 0.8








Thoracic palpitations 26 9.4




Peripheral embolization 0 0
Thrombus formation 8 2.9
Dislodgement 0 0
Embolization 0 0
Arm fracture 10 3.6
Surgical removal of the device 2 0.8
AV  atrioventricular; TIA  transient ischemic attack.















1 36 M N, HLP PFO 4 TIA 2 days none
2 25 F N PFO 1 TIA 2 weeks none
3 48 M N, HYP PFO  ASA 1 TIA 2 months none
4 34 M HYP PFO 2 TIA 5 months none
5 57 F N, HYP PFO 2 TIA 3 weeks none
6 59 F HLP PFO 1 TIA 4 weeks minimal
ASA  atrial septal aneurysm; CVRF  cardiovascular risk factors; HLP  hyperlipidemia; HYP  hypertension; N  smoking; PFO  patent foramen ovale; TEE 
transesophageal echocardiography; TIA  transient ischemic attack.
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was 1.7% for TIA, 0% for stroke, 0% for peripheral
embolism and 1.7% for the combined end point of these
thromboembolic events in our population.
Residual shunt. Complete PFO closure as assessed by
TEE with contrast injection during Valsalva maneuver was
achieved in 83% after 1 month, in 96% after 6 months and
in 99% after 1 year and 2 years. All patients with a residual
shunt had a significant reduction of the shunt degree after
device implantation, as determined by the number of
microbubbles counted in the left atrium (data not shown).
One of these patients with a minimal residual shunt suffered
a TIA. However, according to our data the presence of a
minimal residual shunt after transcatheter closure of the
PFO cannot be considered as a risk factor for recurrent
thromboembolic events (Table 4).
Thrombus formation. Device-adherent thrombus forma-
tions were detected in eight patients (2.9%), either at the
center of the left atrial disc (three patients) or attached to
the expanded nitinol arms (five patients) in generation I and
II devices. The patients were put on oral anticoagulation
initially with intravenous heparin and later with warfarin.
Repetitive TEE examinations showed that the thrombotic
material on the device was completely resolved in all cases.
During the whole observation period none of these patients
were symptomatic or suffered from any thromboembolic
event.
Arm fractures. Arm fractures of generation I devices were
noted in 7 out of 38 patients. However, no embolization of
broken arms/material was associated with the broken struts.
After the introduction of generation II and III devices, only
three arm fractures of generation II devices were detected
since. None were seen in generation III devices. During the
whole follow-up period all patients were clinically asymp-
tomatic and did not suffer a thromboembolic event or
sequalae from the fracture.
Electrocardiography. Detailed analysis of the 12-lead-
ECG at rest and the 24-h Holter-ECGs, which were
performed in 75% of the patients 6 months after device
implantation, revealed no episodes of cardiac arrhythmias
such as atrial fibrillation. A supraventricular tachycardia
with 10 to 18 beats was observed in three patients. A
sinusatrial or an atrioventricular block was not documented
in the follow-up.
DISCUSSION
The present study is based on 345 patient-years and
demonstrates in 276 patients with cryptogenic cerebral
ischemia the peri-interventional complication rate and mid-
term follow-up data after transcatheter PFO closure using
the PFO-Star device.
Reliability of device implantation. Percutaneous PFO
closure with the PFO-Star device was performed with a
success rate of 100% and an overall periprocedural compli-
cation rate of 4%, with most complications being minor and
all being reversible. These included ST-segment elevations
in the inferior leads and a TIA in two patients, most likely
due to air embolism through the trans-septal sheath during
device delivery. The risk of air embolism was significantly
reduced after changing the early cumbersome underwater
loading to a high-pressure flushing delivery system. Air
embolism is a well known peri-interventional complication
during transcatheter PFO closure, which in our study
appears comparable to or less frequent than other studies
(13,14). Irreversible neurologic deficits, retroperitoneal he-
matoma or catheter-induced pericardial effusion were not
observed.
Recurrence of thromboembolic events. During a mean
follow-up of 15.1 months 6 patients reported a recurrent
TIA after transcatheter PFO closure, resulting in an average
annual recurrence rate of 1.7% for TIA, 0% for stroke and
0% for peripheral arterial ischemia. The risk of TIA
recurrence was highest during the first six months after
interventional PFO closure, whereas no patient suffered a
neurologic ischemic event beyond this time point. In all six
cases TEE demonstrated a correct position of the device
with no (five patients) or a minimal (one patient) residual
shunt through the PFO after contrast injection during
Valsalva maneuver. Further evaluation with transcranial
Doppler ultrasound showed a still detectable right-to-left
shunt after injection of saline/air suspension (bubble test) in
one case, suggesting a site of shunt between the venous to
the systemic circulation other than the PFO, which might
be the basis of a recurrent paradoxical embolism. In the
others no residual shunt was present. Similar results were
found by Windecker et al. (13) and others (14,15), who
reported recurrent neurologic ischemic events after success-
ful percutaneous PFO closure (no residual shunt).
Several studies in smaller populations with PFO and
cryptogenic cerebral ischemia were performed, reporting the
risk of recurrent stroke between 0% and 14% (2,3). How-
ever, these data have to be considered with caution, because
stroke prophylactic therapy varied among these groups and
most data resulted from the retrospective analysis of a relative
low number of clinical events and cases. Two large series of
nonselected patients with PFO and stroke were performed
in the mid-1990s. In the multicenter retrospective French
study, 132 patients with a PFO and a history of cryptogenic
cerebral ischemia had an annual recurrence rate of 1.2% for
stroke and 3.4% for TIA (average follow-up 22.6 months)




<1 Month 1–6 Months >6 Months
Recurrent TIA in patients
with residual shunt
2.1% 0% 0%
Recurrent TIA in patients
without residual shunt
1.3% 0.7% 0%
TIA  transient ischemic attack.
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(5). Similar recurrence rates on medical treatment have been
demonstrated by Bogousslavsky et al. (6) in the prospective
Lausanne study. In this study, 140 consecutive patients with
PFO and TIA (16%) or stroke (84%) were treated with
aspirin or warfarin for secondary prevention of recurrent
thromboembolic events. During a mean follow-up of three
years, the annual risk of having a recurrent stroke was 1.9%
versus 3.8% for the combined endpoint of stroke  TIA. A
very recent study of Mas et al. (4) showed slightly lower but
comparable recurrence rates of thromboembolic cerebral
events (TIA  stroke) by 2% per year in a larger
population. It should be pointed out that the data on the
stroke recurrence rate in the present study are not directly
comparable to the follow-up results in these three studies,
because of: 1) the differences in the patient population, 2)
variations in the peri-interventional treatment (such as
clopidogrel for six weeks after PFO closure), and 3) the
various follow-up periods. However, the average annual
recurrence rate of 1.7% for the combined end point of stroke
or TIA after PFO closure with the PFO-Star device
suggests this technique is a promising alternative in the
prevention of thromboembolic events in these patients.
Further studies are necessary to directly compare the medial
and interventional treatment modalities.
Association of the PFO with an ASA. An ASA has been
identified as another source of cardiogenic embolism with a
potential risk for ischemic stroke (4,16). Cabanes et al. (17)
and Mas et al. (4,5) reported that the coexistence of an
ASA  PFO may be an indicator of a higher risk of
recurrent thromboembolic events. Another important find-
ing of our study is that only 1 patient out of 62 with an
ASA  PFO had a recurrent thromboembolic event after
successful percutaneous PFO closure, which is in contrast to
the spontaneous course. None of the patients with a
hypermobile septum had a cerebral ischemic event after
PFO closure. Therefore, these data assume that patients
with the coexistence of an ASA  PFO or hypermobile
septum  PFO have a special benefit from percutaneous
PFO closure, which might be explained by the stabilization
of the aneurysmatic atrial septum between the both discs of
the device, and the closure of the larger PFO opening
associated with an ASA or hypermobile septum.
Postinterventional device-associated thrombus formation.
Device-adherent thrombus formation was observed by TEE
in eight patients (2.9%), either at the center of the left atrial
disc or the left atrial nitinol arms itself. Interestingly, no
thrombotic clots were detected on the right atrial disc.
Because of sufficient anticoagulation, initially with IV hep-
arin and later oral warfarin, the size of the thrombi de-
creased markedly and they were not detectable by repetitive
TEE examination after a maximum of six weeks. All
patients were completely asymptomatic during the whole
follow-up period. Possible explanations for the thrombus
aggregation on the device surface were: 1) insufficient
antiplatelet therapy, 2) a thrombotic potential of the left
atrial nitinol material, and 3) prothrombotic factors of
unknown origin. Therefore, the initial postinterventional
therapeutic regime was empirically changed from aspirin
(100 mg/day) alone to a combination of aspirin and clopi-
dogrel (75 mg/day). Additional progress in the development
of the devices was made from generation II to generation
III, where the expanded nitinol arms were located on the
inner side with the atrial foam facing the left atrial cavum,
thus preventing exposure of the nitinol material to the left
atrium. After these changes, no further thrombotic material
was detected by TEE. Thrombotic clots on the device
surface after transcatheter closure of an atrial septal defect
(PFO and/or ASD) is not a specific complication of the
early generations of the PFO-Star device, but have been
reported in other devices, including the Sideris button (18),
the ASDOS (14) and the DAS-Angel-Wings-device (19).
Therefore, an effective prophylaxis or inhibition of throm-
bus formation on the device surface seems to be very
important.
Endothelization of the PFO-Star device. Endotheliza-
tion of the implanted device by atrial endothelial cells is
important to gain complete percutaneous PFO closure.
Animal experimental data demonstrated a sufficient cell
proliferation, covering the device four weeks after implan-
tation (20). Such endothelization in human heart was
observed one to two weeks after implantation of the device
in one patient, who underwent surgical explantation of the
device, which was slightly dislocated in the PFO channel
after release (see peri-interventional complications). How-
ever, in human heart the detailed time course of endothe-
lization is not known.
Clinical predictors of stroke recurrence after percutane-
ous PFO closure. Windecker et al. reported in 80 patients
using different occlusion systems that the presence of a
postprocedural residual shunt might be associated with an
increased risk of stroke recurrence after PFO closure (13).
In contrast, the data of the present study demonstrate in a
larger patient population that the existence of a residual
shunt did not correlate with an increased recurrence rate of
thromboembolic events after transcatheter PFO closure.
Thus, five patients with a recurrent TIA did not have a
residual shunt, whereas only one patient had both a TIA
and a minimal residual shunt. As specified, all of the
patients with a thromboembolic recurrent event were found
to have at least one cardiovascular risk factor.
Conclusions. The present study is based on 276 consecu-
tive patients with a PFO and a history of cryptogenic
cerebral or peripheral ischemia who underwent percutane-
ous PFO closure. The presented data report the transcath-
eter PFO closure with the PFO-Star device as a reliable and
feasible technique with a relatively low thromboembolic
recurrence rate during the follow-up period of up to 34
months. However, prospective and randomized clinical
trials are necessary to directly compare the interventional
PFO closure with other treatment modalities such as
antiplatelet therapy, oral anticoagulation and surgical repair
of the PFO.
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